Orgenesis Announces Results From A Real-World Study Of ORG-101 CAR-T Therapy In Patients With CD19+ Acute Lymphoblastic Leukemia; Top-Line Efficacy And Safety Data From The Study Had A Complete Response Of 82% In Adult Patients And 93% In Pediatric Patients
Portfolio Pulse from Benzinga Newsdesk
Orgenesis Inc. announced positive results from a real-world study of its ORG-101 CAR-T therapy, showing high complete response rates in both adult and pediatric patients with CD19+ Acute Lymphoblastic Leukemia. The study also indicated a favorable safety profile with low incidence of severe Cytokine Release Syndrome. Harley Street Healthcare Group plans to collaborate with Orgenesis to establish a Global Cancer Initiative to further develop and democratize advanced therapies.
August 29, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Orgenesis Inc. reported high efficacy and a favorable safety profile for its ORG-101 CAR-T therapy in a real-world study, potentially boosting investor confidence. The partnership with Harley Street Healthcare Group to establish a Global Cancer Initiative could further enhance the company's market position.
The positive clinical trial results for ORG-101 CAR-T therapy, with high complete response rates and low severe CRS incidence, are likely to boost investor confidence in Orgenesis. Additionally, the partnership with Harley Street Healthcare Group to establish a Global Cancer Initiative could lead to further advancements and market opportunities, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100